NCT02032875View on ClinicalTrials.gov

Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant

PHASE3CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

January 31, 2016

Conditions
Hepatitis C
Interventions
DRUG

Daclatasvir

DRUG

Sofosbuvir

DRUG

Ribavirin

Trial Locations (5)

33136

University Of Miami Schiff Center For Liver Diseases, Miami

48109

University Of Michigan Health System, Ann Arbor

77030

Baylor St. Luke'S Medical Center, Houston

78215

American Research Corporation, San Antonio

98104

Harborview Medical Center, Seattle

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY